Clene (CLNN) announced the presentation of the combined REPAIR-MS results across relapsing MS and non-active progressive MS during the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, held September 24-26, 2025, in Barcelona, Spain. Key findings from CNM-Au8 treatment include: The mean NAD+/NADH ratio in the brain was significantly increased following 12 weeks of treatment with CNM-Au8 in the full REPAIR population. The change in REPAIR-MS participants alone demonstrated consistent increases in the NAD+/NADH ratio to Week 12, a measure of how efficiently the brain makes energy. Secondary endpoints: the change in the % fraction of brain NAD+ and NADH similarly demonstrated statistically significant increases in NAD+ and decreases in NADH for both the full REPAIR population and REPAIR-MS, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Clene price target lowered to $31 from $33 at Benchmark
- Clene Expands Equity Distribution to Raise Capital
- Clene files to sell 491,496 shares of common stock for holders
- Clene’s CNM-Au8 Shows Promise in Parkinson’s Treatment, Justifying Buy Rating
- Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease